The pathogenesis of chronic lymphocytic leukemia

Annual Review of Pathology: Mechanisms of Disease

Volumn 9, Issue , 2014, Pages 103-118

  Zhang, Suping ^a   Kipps, Thomas J ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

B cell signaling; Cell origin; Genetic alterations; Microenvironment

Indexed keywords

B LYMPHOCYTE; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; DISEASE COURSE; GENE EXPRESSION; GENETICS; HUMAN; IMMUNOLOGY; PATHOLOGY; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

B-LYMPHOCYTES; CELL PROLIFERATION; CELLULAR MICROENVIRONMENT; DISEASE PROGRESSION; GENE EXPRESSION; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; SIGNAL TRANSDUCTION;

EID: 84897018638     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev-pathol-020712-163955     Document Type: Article

References (120)

1. Chiorazzi N, Rai KR, Ferrarini M. 2005. Chronic lymphocytic leukemia. N. Engl. J. Med. 352:804-15
2. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, et al. 2008. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, vol. 2. Geneva, Switz.:WHO. 4th ed.
3. Dighiero G, Travade P, Chevret S, Fenaux P, Chastang C, Binet JL. 1991. B-cell chronic lymphocytic leukemia: present status and future directions. French Cooperative Group on CLL. Blood 78:1901-14
4. Ponzoni M, Doglioni C, Caligaris-Cappio F. 2011. Chronic lymphocytic leukemia: the pathologists view of lymph node microenvironment. Semin. Diagn. Pathol. 28:161-66
5. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. 2009. The microenvironment in mature B cell malignancies: a target for new treatment strategies. Blood 114:3367-75
6. Ratech H, Sheibani K, Nathwani BN, Rappaport H. 1988. Immunoarchitecture of the "pseudofollicles" of well-differentiated (small) lymphocytic lymphoma: a comparison with true follicles. Hum. Pathol. 19:89-94
7. Schmid C, Isaacson PG. 1994. Proliferation centres in B cell malignant lymphoma, lymphocytic (B-CLL): an immunophenotypic study. Histopathology 24:445-51
8. Soma LA, Craig FE, Swerdlow SH. 2006. The proliferation center microenvironment and prognostic markers in chronic lymphocytic leukemia/small lymphocytic lymphoma. Hum. Pathol. 37:152-59
9. Vandewoestyne ML, Pede VC, Lambein KY, Dhaenens MF, Offner FC, et al. 2011. Laser microdissection for the assessment of the clonal relationship between chronic lymphocytic leukemia/small lymphocytic lymphoma and proliferating B cells within lymph node pseudofollicles. Leukemia 25:883-88
10. Messmer BT, Messmer D, Allen SL, Kolitz JE, Kudalkar P, et al. 2005. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J. Clin. Investig. 115:755-64
11. Zenz T, Mertens D, Kuppers R, Dohner H, Stilgenbauer S. 2010. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat. Rev. Cancer 10:37-50
12. Zenz T, Gribben JG, Hallek M, Dohner H, Keating MJ, Stilgenbauer S. 2012. Risk categories and refractory CLL in the era of chemoimmunotherapy. Blood 119:4101-7
13. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, et al. 1999. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94:1840-47
14. Barrett-Connor E, Stuenkel C. 1999. Hormones and heart disease in women: Heart and Estrogen/Progestin Replacement Study in perspective. J. Clin. Endocrinol. Metab. 84:1848-53
15. Caligaris-Cappio F, Gobbi M, Bofill M, Janossy G. 1982. Infrequent normal B lymphocytes express features of B chronic lymphocytic leukemia. J. Exp. Med. 155:623-28
16. Caligaris-Cappio F. 1996. B chronic lymphocytic leukemia: a malignancy of anti-self B cells. Blood 87:2615-20
17. Dono M, Burgio VL, Colombo M, Sciacchitano S, Reverberi D, et al. 2007. CD5+ B cells with the features of subepithelial B cells found in human tonsils. Eur. J. Immunol. 37:2138-47
18. Chiorazzi N, Ferrarini M. 2011. Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities. Blood 117:1781-91
19. Forconi F, Potter KN, Wheatley I, Darzentas N, Sozzi E, et al. 2010. The normal IGHV1-69-derived B cell repertoire contains stereotypic patterns characteristic of unmutated CLL. Blood 115:71-77
20. Klein U, Tu Y, Stolovitzky GA, Mattioli M, Cattoretti G, et al. 2001. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J. Exp. Med. 194:1625-38
21. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, et al. 2001. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J. Exp. Med. 194:1639-47
22. Sims GP, Ettinger R, Shirota Y, Yarboro CH, Illei GG, Lipsky PE. 2005. Identification and characterization of circulating human transitional B cells. Blood 105:4390-98
23. Ha YJ, Mun YC, Seong CM, Lee JR. 2008. Characterization of phenotypically distinct B cell subsets and receptor-stimulated mitogen-Activated protein kinase activation in human cord blood B cells. J. Leukoc. Biol. 84:1557-64
24. Marie-Cardine A, Divay F, Dutot I, Green A, Perdrix A, et al. 2008. Transitional B cells in humans: characterization and insight from B lymphocyte reconstitution after hematopoietic stem cell transplantation. Clin. Immunol. 127:14-25
25. Seifert M, Sellmann L, Bloehdorn J, Wein F, Stilgenbauer S, et al. 2012. Cellular origin and pathophysiology of chronic lymphocytic leukemia. J. Exp. Med. 209:2183-98
26. Rawstron AC, Yuille MR, Fuller J, Cullen M, Kennedy B, et al. 2002. Inherited predisposition to CLL is detectable as subclinical monoclonal B lymphocyte expansion. Blood 100:2289-90
27. Rawstron AC, Green MJ, Kuzmicki A, Kennedy B, Fenton JA, et al. 2002. Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. Blood 100:635-39
28. Ghia P, Prato G, Scielzo C, Stella S, GeunaM, et al. 2004. Monoclonal CD5+ and CD5- B lymphocyte expansions are frequent in the peripheral blood of the elderly. Blood 103:2337-42
29. Rawstron AC, Bennett FL, OConnor SJ, Kwok M, Fenton JA, et al. 2008. Monoclonal B cell lymphocytosis and chronic lymphocytic leukemia. N. Engl. J. Med. 359:575-83
30. Roulland S, Navarro JM, Grenot P, Milili M, Agopian J, et al. 2006. Follicular lymphoma-like B cells in healthy individuals: a novel intermediate step in early lymphomagenesis. J. Exp. Med. 203:2425-31
31. Baskar S, Kwong KY, Hofer T, Levy JM, Kennedy MG, et al. 2008. Unique cell surface expression of receptor tyrosine kinaseROR1 in human B cell chronic lymphocytic leukemia. Clin. Cancer Res. 14:396-404
32. Daneshmanesh AH, Mikaelsson E, Jeddi-Tehrani M, Bayat AA, Ghods R, et al. 2008. ROR1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy. Int. J. Cancer 123:1190-95
33. Fukuda T, Chen L, Endo T, Tang L, Lu D, et al. 2008. Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc. Natl. Acad. Sci. USA 105:3047-52
34. Zhang S, Chen L, Cui B, Chuang HY, Yu J, et al. 2012. ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth. PLoS ONE 7:e31127
35. Zhang S, Chen L, Wang-Rodriguez J, Zhang L, Cui B, et al. 2012. The onco-embryonic antigen ROR1 is expressed by a variety of human cancers. Am. J. Pathol. 181:1903-10
36. Broome HE, Rassenti LZ, Wang HY, Meyer LM, Kipps TJ. 2011. ROR1 is expressed on hematogones (non-neoplastic human B lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia. Leuk. Res. 35:1390-94
37. Sevilla DW, Colovai AI, Emmons FN, Bhagat G, Alobeid B. 2010. Hematogones: a review and update. Leuk. Lymphoma 51:10-19
38. Milleck J, Kreuzer K-A, Med D, Assenmacher M, Schmitz J, Jaha PS. 2012. Characterization of peripheral B cells expressing CLL-Associated receptor tyrosine kinase ROR1 in healthy donors. Presented at Meet. Am. Soc. Hematol., Atlanta
39. Kikushige Y, Ishikawa F, Miyamoto T, Shima T, Urata S, et al. 2011. Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. Cancer Cell 20:246-59
40. Damle RN, Batliwalla FM, Ghiotto F, Valetto A, Albesiano E, et al. 2004. Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobulin V gene mutations. Blood 103:375-82
41. Cooper MD, Alder MN. 2006. The evolution of adaptive immune systems. Cell 124:815-22
42. Widhopf GF 2nd, Goldberg CJ, Toy TL, Rassenti LZ, Wierda WG, et al. 2008. Nonstochastic pairing of immunoglobulin heavy and light chains expressed by chronic lymphocytic leukemia B cells is predicated on the heavy chain CDR3. Blood 111:3137-44
43. Kipps TJ. 1993. Immunoglobulin genes in chronic lymphocytic leukemia. Blood Cells 19:615-25; discussion 631-32
44. Chiorazzi N, Ferrarini M. 2003. B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Annu. Rev. Immunol. 21:841-94
45. Stevenson FK, Caligaris-Cappio F. 2004. Chronic lymphocytic leukemia: revelations from the B cell receptor. Blood 103:4389-95
46. Fais F, Ghiotto F, Hashimoto S, Sellars B, Valetto A, et al. 1998. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J. Clin. Investig. 102:1515-25
47. Myhrinder AL, Hellqvist E, Sidorova E, Soderberg A, Baxendale H, et al. 2008. A new perspective: Molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. Blood 111:3838-48
48. Catera R, Silverman GJ, Hatzi K, Seiler T, Didier S, et al. 2008. Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation. Mol. Med. 14:665-74
49. Chu CC, Catera R, HatziK, Yan XJ, Zhang L, et al. 2008. Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA. Blood 112:5122-29
50. Seiler T, Woelfle M, Yancopoulos S, Catera R, Li W, et al. 2009. Characterization of structurally defined epitopes recognized by monoclonal antibodies produced by chronic lymphocytic leukemia B cells. Blood 114:3615-24
51. Chu CC, Catera R, Zhang L, Didier S, Agagnina BM, et al. 2010. Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin. Blood 115:3907-15
52. Stamatopoulos K. 2010. Antigens in CLL: themes and variations. Blood 115:3855-56
53. Landgren O, Rapkin JS, Caporaso NE, Mellemkjaer L, Gridley G, et al. 2007. Respiratory tract infections and subsequent risk of chronic lymphocytic leukemia. Blood 109:2198-201
54. Kostareli E, Hadzidimitriou A, Stavroyianni N, Darzentas N, Athanasiadou A, et al. 2009. Molecular evidence for EBV and CMV persistence in a subset of patients with chronic lymphocytic leukemia expressing stereotyped IGHV4-34 B cell receptors. Leukemia 23:919-24
55. Steininger C, Rassenti LZ, Vanura K, Eigenberger K, Jager U, et al. 2009. Relative seroprevalence of human herpes viruses in patients with chronic lymphocytic leukaemia. Eur. J. Clin. Investig. 39:497-506
56. Steininger C, Widhopf GF 2nd, Ghia EM, Morello CS, Vanura K, et al. 2012. Recombinant antibodies encoded by IGHV1-69 react with pUL32, a phosphoprotein of cytomegalovirus and B cell superantigen. Blood 119:2293-301
57. Kostareli E, GounariM, Janus A, Murray F, Brochet X, et al. 2012. Antigen receptor stereotypy across B cell lymphoproliferations: the case of IGHV4-59/IGKV3-20 receptors with rheumatoid factor activity. Leukemia 26:1127-31
58. Gaidano G, Foa R, Dalla-Favera R. 2012. Molecular pathogenesis of chronic lymphocytic leukemia. J. Clin. Investig. 122:3432-38
59. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, et al. 2000. Genomic aberrations and survival in chronic lymphocytic leukemia. N. Engl. J. Med. 343:1910-16
60. Caporaso N, Goldin L, Plass C, Calin G, Marti G, et al. 2007. Chronic lymphocytic leukaemia genetics overview. Br. J. Haematol. 139:630-34
61. Fabbri G, Rasi S, Rossi D, Trifonov V, Khiabanian H, et al. 2011. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J. Exp. Med. 208:1389-401
62. Puente XS, Pinyol M, Quesada V, Conde L, Ordonez GR, et al. 2011. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475:101-5
63. Quesada V, Conde L, Villamor N, Ordonez GR, Jares P, et al. 2012. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat. Genet. 44:47-52
64. Wang L, Lawrence MS, Wan Y, Stojanov P, Sougnez C, et al. 2011. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N. Engl. J. Med. 365:2497-506
65. Rossi D, Bruscaggin A, Spina V, Rasi S, Khiabanian H, et al. 2011. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine refractoriness. Blood 118:6904-8
66. Rossi D, Rasi S, Fabbri G, Spina V, Fangazio M, et al. 2012. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood 119:521-29
67. Rossi D, Fangazio M, Rasi S, Vaisitti T, Monti S, et al. 2012. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood 119:2854-62
68. Rothenberg EV. 2011. T cell lineage commitment: identity and renunciation. J. Immunol. 186:6649-55
69. Santos MA, Sarmento LM, Rebelo M, Doce AA, Maillard I, et al. 2007. Notch1 engagement by Delta-like-1 promotes differentiation of B lymphocytes to antibody-secreting cells. Proc. Natl. Acad. Sci. USA 104:15454-59
70. Ferrando AA. 2009. The role of NOTCH1 signaling in T-ALL. Hematol. Am. Soc. Hematol. Educ. Program 353-61
71. Balatti V, Bottoni A, Palamarchuk A, Alder H, Rassenti LZ, et al. 2012. NOTCH1 mutations in CLL associated with trisomy 12. Blood 119:329-31
72. Del Giudice I, Rossi D, Chiaretti S, Marinelli M, Tavolaro S, et al. 2012. NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL. Haematologica 97:437-41
73. Wahl MC, Will CL, Luhrmann R. 2009. The spliceosome: design principles of a dynamic RNP machine. Cell 136:701-18
74. Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, et al. 2013. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152:714-26
75. Schwaederle M, Ghia E, Rassenti LZ, Obara M, DellAquila ML, et al. 2013. Subclonal evolution involving SF3B1 mutations in chronic lymphocytic leukemia. Leukemia 27:1214-17
76. Vallabhapurapu S, Karin M. 2009. Regulation and function of NF-κB transcription factors in the immune system. Annu. Rev. Immunol. 27:693-733
77. Endo T, Nishio M, EnzlerT, CottamHB, Fukuda T, et al. 2007. BAFF and APRIL support chronic lymphocytic leukemia B cell survival through activation of the canonical NF-κB pathway. Blood 109:703-10
78. Enzler T, Kater AP, Zhang W, Widhopf GF 2nd, Chuang HY, et al. 2009. Chronic lymphocytic leukemia of Emu-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression. Blood 114:4469-76
79. ZhangW, Kater AP, Widhopf GF 2nd, Chuang HY, Enzler T, et al. 2010. B cell activating factor and v-Mycmyelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA 107:18956-60
80. Hewamana S, Lin TT, Jenkins C, Burnett AK, Jordan CT, et al. 2008. The novel nuclear factor κB inhibitor LC-1 is equipotent in poor prognostic subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine. Clin. Cancer Res. 14:8102-11
81. Hertlein E, Wagner AJ, Jones J, Lin TS, Maddocks KJ, et al. 2010. 17-DMAG targets the nuclear factor κB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition. Blood 116:45-53
82. Treon SP, Xu L, Yang G, Zhou, Y, Liu X, et al. 2012. MYD88 L265P somatic mutation in Waldenstroms macroglobulinemia. N. Engl. J. Med. 367:826-33
83. Deaglio S, Vaisitti T, Bergui L, Bonello L, Horenstein AL, et al. 2005. CD38 and CD100 lead a network of surface receptors relaying positive signals for B-CLL growth and survival. Blood 105:3042-50
84. Malavasi F, Deaglio S, Damle R, Cutrona G, Ferrarini M, Chiorazzi N. 2011. CD38 and chronic lymphocytic leukemia: a decade later. Blood 118:3470-78
85. Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, et al. 2011. Oncogenically active MYD88 mutations in human lymphoma. Nature 470:115-19
86. Gutierrez A Jr, Tschumper RC, Wu X, Shanafelt TD, Eckel-Passow J, et al. 2010. LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B cell lymphocytosis. Blood 116:2975-83
87. Lu D, Zhao Y, Tawatao R, Cottam HB, Sen M, et al. 2004. Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA 101:3118-23
88. Lu D, Liu JX, Endo T, Zhou H, Yao S, et al. 2009. Ethacrynic acid exhibits selective toxicity to chronic lymphocytic leukemia cells by inhibition of theWnt/β-catenin pathway. PLoS ONE 4:e8294
89. Lu D, Choi MY, Yu J, Castro JE, Kipps TJ, Carson DA. 2011. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc.Natl. Acad. Sci. USA108:13253-57
90. Wu CJ. 2012. CLL clonal heterogeneity: an ecology of competing subpopulations. Blood 120:4117-18
91. Schuh A, Becq J, Humphray S, Alexa A, Burns A, et al. 2012. Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. Blood 120:4191-96
92. Woyach JA, Johnson AJ, Byrd JC. 2012. The B cell receptor signaling pathway as a therapeutic target in CLL. Blood 120:1175-84
93. Chen L, Apgar J, Huynh L, Dicker F, Giago-McGahan T, et al. 2005. ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. Blood 105:2036-41
94. Chen L, Huynh L, Apgar J, Tang L, Rassenti L, et al. 2008. ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia. Blood 111:2685-92
95. Duhren-von Minden M, Ubelhart R, Schneider D, Wossning T, Bach MP, et al. 2012. Chronic lymphocytic leukaemia is driven by antigen-independent cell-Autonomous signalling. Nature 489:309-12
96. Burger JA, Quiroga MP, Hartmann E, Burkle A, Wierda WG, et al. 2009. High-level expression of the T cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood 113:3050-58
97. Patten PE, Buggins AG, Richards J, Wotherspoon A, Salisbury J, et al. 2008. CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. Blood 111:5173-81
98. Ghia P, Strola G, Granziero L, Geuna M, Guida G, et al. 2002. Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22. Eur. J. Immunol. 32:1403-13
99. Herishanu Y, Perez-Galan P, Liu D, Biancotto A, Pittaluga S, et al. 2011. The lymph node microenvironment promotes B cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 117:563-74
100. Ibrahim S, Keating M, Do KA, OBrien S, Huh YO, et al. 2001. CD38 expression as an important prognostic factor in B cell chronic lymphocytic leukemia. Blood 98:181-86
101. Damle RN, Temburni S, Calissano C, Yancopoulos S, Banapour T, et al. 2007. CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells. Blood 110:3352-59
102. Deaglio S, Aydin S, Grand MM, Vaisitti T, Bergui L, et al. 2010. CD38/CD31 interactions activate genetic pathways leading to proliferation and migration in chronic lymphocytic leukemia cells. Mol. Med. 16:87-91
103. Buggins AG, Levi A, Gohil S, FishlockK, Patten PE, et al. 2011. Evidence for a macromolecular complex in poor prognosis CLL that contains CD38, CD49d, CD44 and MMP-9. Br. J. Haematol. 154:216-22
104. Zhang S, Wu CCN, Fecteau J-F, Cui B, Chen L, et al. 2013. Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44. Proc. Natl. Acad. Sci. USA 110:6127-32
105. Burger JA, Burger M, Kipps TJ. 1999. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood 94:3658-67
106. Bennett F, Rawstron A, Plummer M, de Tute R, Moreton P, et al. 2007. B cell chronic lymphocytic leukaemia cells show specific changes in membrane protein expression during different stages of cell cycle. Br. J. Haematol. 139:600-4
107. Burger JA, TsukadaN, BurgerM, Zvaifler NJ, DellAquila M, Kipps TJ. 2000. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor 1. Blood 96:2655-63
108. Burger M, Hartmann T, Krome M, Rawluk J, Tamamura H, et al. 2005. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood 106:1824-30
109. Nishio M, Endo T, TsukadaN, Ohata J, Kitada S, et al. 2005. Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1α. Blood 106:1012-20
110. Calissano C, Damle RN, Hayes G, Murphy EJ, Hellerstein MK, et al. 2009. In vivo intraclonal and interclonal kinetic heterogeneity in B cell chronic lymphocytic leukemia. Blood 114:4832-42
111. Quiroga MP, Balakrishnan K, Kurtova AV, Sivina M, Keating MJ, et al. 2009. B cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood 114:1029-37
112. Vlad A, Deglesne PA, Letestu R, Saint-Georges S, Chevallier N, et al. 2009. Down-regulation of CXCR4 and CD62L in chronic lymphocytic leukemia cells is triggered by B cell receptor ligation and associated with progressive disease. Cancer Res. 69:6387-95
113. Muzio M, Scielzo C, Bertilaccio MT, Frenquelli M, Ghia P, Caligaris-Cappio F. 2009. Expression and function of Toll-like receptors in chronic lymphocytic leukaemia cells. Br. J. Haematol. 144:507-16
114. Burger JA, Montserrat E. 2012. Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B cell receptor signaling. Blood 121:1501-9
115. SteinH, Bonk A, TolksdorfG, Lennert K, Rodt H, Gerdes J. 1980. Immunohistologic analysis of the organization of normal lymphoid tissue and non-Hodgkins lymphomas. J. Histochem. Cytochem. 28:746-60
116. Ruan J, HyjekE, Kermani P, Christos PJ, HooperAT, et al. 2006. Magnitude of stromal hemangiogenesis correlates with histologic subtype of non-Hodgkins lymphoma. Clin. Cancer Res. 12:5622-31
117. Tsukada N, Burger JA, Zvaifler NJ, Kipps TJ. 2002. Distinctive features of "nurselike" cells that differentiate in the context of chronic lymphocytic leukemia. Blood 99:1030-37
118. Burger JA. 2010. Chemokines and chemokine receptors in chronic lymphocytic leukemia (CLL): from understanding the basics towards therapeutic targeting. Semin. Cancer Biol. 20:424-30
119. Panayiotidis P, Jones D, Ganeshaguru K, Foroni L, Hoffbrand AV. 1996. Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br. J. Haematol. 92:97-103
120. Lagneaux L, Delforge A, Bron D, De Bruyn C, Stryckmans P. 1998. Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood 91:2387-96